Heart Pump Redirected to Heart Attack Shock Patients
Boston Scientific's Vitalyst, backed by up to $455 million from Blackstone, now targets patients in cardiogenic shock.
Updated on Nov. 5, 2026 in Heart Disease
Blackstone Life Sciences agreed to provide up to $455 million to co-fund development of Boston Scientific's Vitalyst, a miniature temporary heart pump, in an agreement disclosed Monday. The program has been refocused toward patients in cardiogenic shock caused by acute myocardial infarction, a heart attack.
Why it matters
Temporary mechanical support devices can help keep blood circulating while a failing heart recovers or is stabilized, so the choice of which patients a device targets shapes who may eventually have access to it. Boston Scientific moved Vitalyst away from high-risk coronary procedure patients after March research found that a competing heart pump, Johnson & Johnson's Impella, did not lower the risk of major adverse events in complex procedures.
The financing terms come from a company disclosure rather than clinical data. The cited market figures are forward projections, and the source does not report trial results for Vitalyst itself.
The players
Boston Scientific
A medical device company whose cardiovascular portfolio includes catheter-based heart therapies such as the Vitalyst heart pump.
Blackstone Life Sciences
The life sciences investment arm of Blackstone that provides financing to clinical-stage medical and pharmaceutical programs.
Food and Drug Administration
The U.S. federal agency responsible for approving medical devices and drugs, which approved a Vitalyst percutaneous coronary intervention study.
The details
Vitalyst is a miniature heart pump that provides temporary mechanical circulatory support, meaning it takes over part of the heart's pumping work for a limited period. It uses a magnetically driven impeller, and its catheter and motor design is intended to improve positional stability and reduce hemolysis, the breakdown of red blood cells that can occur with blood pumps. Under the arrangement, Blackstone will co-fund development in exchange for regulatory and commercial milestone payments plus royalties on net sales.
Timeline
March 2026: Research reported that Impella failed to lower major adverse event risk in complex PCI patients.
May 2025: Boston Scientific's CEO called Vitalyst the largest investment the company has made, at a Bernstein event.
November 2, 2026: The third-quarter earnings call discussed the shift in Vitalyst's focus.
November 3, 2026: Blackstone disclosed the $455 million agreement.
2030: Boston Scientific expects to begin making payments to Blackstone.
Health Landscape
Temporary heart pumps are used in several settings, and the market for them is projected to grow substantially through 2035. Boston Scientific's shift toward cardiogenic shock after a competitor's disappointing high-risk procedure data reflects how device developers are narrowing indications as evidence accumulates.
If you have a history of heart attack or heart failure, these developments are a reason to ask your cardiologist which heart-support options, if any, are appropriate for your situation. Device indications are narrowing, so questions about eligibility are worth raising at your next specialist visit.
The takeaway
Device developers are narrowing which patients their heart pumps target as clinical results come in, so the population a device is studied in matters. Ask your physician whether temporary circulatory support is relevant to any heart condition you are managing.
Further reading
For more on the conditions these devices treat, browse our Heart Disease coverage.
Source note: This article includes information reported by MedTech Dive.
